Home / News
Illumina, OrigiMed Collaborate to Develop Cancer Assays
2018/9/10 16:19:02 Views£º762
NEW YORK (GenomeWeb) ¨C Shanghai, China-based cancer precision medicine company OrigiMed said today it will collaborate with Illumina to develop oncology assays.
The firms will develop the new assays on Illumina's next-generation sequencing instruments for cancer molecular diagnostics. OrigiMed will also develop a bioinformatics solution for medical institutions.
OrigiMed is currently equipped with one of Illumina's NovaSeq 6000, four NextSeq 500s and one MiniSeq.
- CAIVD WeChat
Subscription Account
- CAIVD WeChat
Channels
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.